Aresa publishes data on the expression of the Rhesus D (RhD) antibody in tobacco plants.

First North Announcement no. 10 2007/ 27th June, 2007

Copenhagen, 27th June, 2007

Resume: The plant biotech company Aresa has published data on the
expression of the Rhesus D (RhD) antibody in transiently         
transformed tobacco plants.                                      

Aresa publishes data on the expression of the Rhesus D (RhD)
antibody in tobacco plants.                                 

As part of the explorative work within the BioPharma business area, Aresa has 
published data on the expression of the Rhesus D (RhD) antibody in transiently
transformed tobacco plants at a plant biotech conference in Verona, Italy.    

Monoclonal anti Rhesus D IgG1 antibodies are used in diagnostic tests in the
identification of the Rhesus D+ RhD+ blood typing.                          

In order to investigate the potential of a transient transformation system of   
tobacco the human Rhesus D antibody (RhD ab) was used as a test candidate and   
compared to the biological activity and diagnostic usefulness of the            
traditionally expressed antibody in Chinese Hamster Ovary (CHO) cells.          

The conclusions from the work are that by using a transient transformation assay
in tobacco, the production and subsequent purification of the antibody can be   
done in less than two weeks and is a very low cost process.                     

The functionality of recombinant expressed RhD antibody in tobacco was tested   
and the specificity of the antibody was found to be just as good as recombinant 
RhD antibody produced in CHO cells.                                             

The work was done a part of capacity building in Aresa BioPharma and as part of 
building experience working with new plant systems. It is not anticipated that  
the RhD antibody will become a future business area.                            

The content of this press release is not expected to have impact on the result  
for the current fiscal year.                                                    

Best regards,

Jarne Elleholm
CEO           
Aresa A/S     

Further information can be obtained by contacting Jarne Elleholm, CEO for Aresa 
A/S on +45 70227747, mobile: +45 41190136 or to the company's financial advisor 
HSH Gudme Corporate Finance A/S, Morten Kjærulff, Director, +45 33449431.       

About Aresa                                                                     
Aresa is a plant biotech company established in 2001 by the company's current   
CSO, Carsten Meier and has origins from the Institute of Molecular Biology at   
Copenhagen University.                                                          

Aresa has developed two plant based technology platforms, BioSensor for the     
detection of substances in soil, hereunder evaporation of explosives from       
landmines; and BioPharma, a tool for the optimisation and production of         
antibodies and proteins in plants.                                              

Aresa was listed on the Copenhagen OMX-First North market place in 2006. Aresa  
is based at Symbion Science Park in Copenhagen and has greenhouse facilities in 
the outskirts of Copenhagen and test areas in Denmark, Croatia and now also in  
Bosnia Herzegovina. Aresa has 16 employees, hereof 8 within research and        
development and 5 within landmine operations.